Infographic: ranibizumab or bevacizumab treat & extend for neovascular age-related macular degeneration (AMD): LUCAS trial.
作者信息
Barai Ishani, Sivaprasad Sobha, Henein Christin
机构信息
UCL Institute of Ophthalmology, London, UK.
出版信息
Eye (Lond). 2025 Feb;39(Suppl 1):129-131. doi: 10.1038/s41433-024-03339-z. Epub 2024 Sep 18.
Abstract
摘要
相似文献
1
Infographic: ranibizumab or bevacizumab treat & extend for neovascular age-related macular degeneration (AMD): LUCAS trial.信息图：雷珠单抗或贝伐单抗治疗并延长用于新生血管性年龄相关性黄斑变性（AMD）：LUCAS试验。
Eye (Lond). 2025 Feb;39(Suppl 1):129-131. doi: 10.1038/s41433-024-03339-z. Epub 2024 Sep 18.
2
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.贝伐单抗与雷珠单抗治疗新生血管性年龄相关性黄斑变性的全身安全性。
Cochrane Database Syst Rev. 2014 Sep 15;9(9):CD011230. doi: 10.1002/14651858.CD011230.pub2.
3
Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.根据 LUCAS 治疗和扩展方案比较雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性。
Ophthalmology. 2015 Jan;122(1):146-52. doi: 10.1016/j.ophtha.2014.07.041. Epub 2014 Sep 13.
4
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration.一项关于按需治疗与延长雷珠单抗或贝伐单抗治疗方案用于新生血管性年龄相关性黄斑变性的系统评价。
Br J Ophthalmol. 2016 Jul;100(7):914-917. doi: 10.1136/bjophthalmol-2015-306987. Epub 2015 Oct 29.
5
Aflibercept for neovascular age-related macular degeneration.阿柏西普用于治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2016 Feb 8;2(2):CD011346. doi: 10.1002/14651858.CD011346.pub2.
6
A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.抗血管内皮生长因子药物治疗新生血管性年龄相关性黄斑变性的疗效和安全性结局的系统评价：雷珠单抗和贝伐单抗的比较。
Curr Med Res Opin. 2011 Jul;27(7):1465-75. doi: 10.1185/03007995.2011.585394. Epub 2011 May 31.
7
Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.用于治疗新生血管性年龄相关性黄斑变性的抗血管内皮生长因子药物给药治疗方案。
Cochrane Database Syst Rev. 2020 May 5;5(5):CD012208. doi: 10.1002/14651858.CD012208.pub2.
8
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.抗血管内皮生长因子用于治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2014 Aug 29;8(8):CD005139. doi: 10.1002/14651858.CD005139.pub3.
9
Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment.雷珠单抗和贝伐单抗交替双周玻璃体内注射治疗伴有色素上皮脱离的难治性新生血管性年龄相关性黄斑变性
Semin Ophthalmol. 2017;32(3):309-315. doi: 10.3109/08820538.2015.1072222. Epub 2015 Sep 4.
10
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.抗血管内皮生长因子用于治疗新生血管性年龄相关性黄斑变性。
Cochrane Database Syst Rev. 2019 Mar 4;3(3):CD005139. doi: 10.1002/14651858.CD005139.pub4.
本文引用的文献
1
Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results.雷珠单抗或贝伐单抗治疗新生血管性年龄相关性黄斑变性 Lucentis 对比 Avastin 研究中的按需治疗和扩展方案：两年结果。
Ophthalmology. 2016 Jan;123(1):51-9. doi: 10.1016/j.ophtha.2015.09.018. Epub 2015 Oct 21.
2
Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.根据 LUCAS 治疗和扩展方案比较雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性。
Ophthalmology. 2015 Jan;122(1):146-52. doi: 10.1016/j.ophtha.2014.07.041. Epub 2014 Sep 13.
Zotero 插件